Related Experiment Video
Updated: Sep 3, 2025
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
8.0K
Antigen-specific immunotherapies in type 1 diabetes
Xuejiao Zhang1, Ying Dong2, Dianyuan Liu1
1Department of Endocrinology, China-Japan Union Hospital of Jilin University, Changchun 130000, China.
Summary
Antigen-specific immunotherapy targeting zinc transporter 8 (ZnT8) shows promise for preventing and treating type 1 diabetes mellitus (T1DM). This approach aims to restore pancreatic beta cell function by inducing self-tolerance, offering new therapeutic avenues.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Type 1 diabetes mellitus (T1DM) is an autoimmune disease targeting pancreatic beta cells.
- Immune system dysregulation is central to T1DM pathogenesis.
- Restoring beta cell function and finding a cure for T1DM remain critical goals.
Purpose of the Study:
- To review antigen-specific immunotherapies (ASI) for T1DM over the last decade.
- To highlight the zinc transporter 8 (ZnT8) antigen as a key target for immunotherapy.
- To explore ZnT8's role in T1DM autoimmunity and its potential for inducing self-tolerance.
Main Methods:
- Review of recent research on ASI for T1DM.
- Analysis of ZnT8's immunogenicity and role in T1D autoimmune responses.
- Examination of ZnT8-specific CD8+ T cell involvement in T1DM progression.
Main Results:
- Immune regulation using pancreatic islet auto-antigens is a specific and safe T1DM treatment strategy.
- ZnT8 is an immunogenic auto-antigen present in pre-diabetic and diabetic patients, significant for early T1D diagnosis.
- ZnT8-specific CD8+ T cells are prevalent in T1DM patients and drive disease progression.
Conclusions:
- Antigen-based immunotherapy offers novel strategies for T1DM prevention and treatment.
- Targeting ZnT8 can induce self-tolerance, potentially preventing T1DM in high-risk individuals and slowing autoimmunity in pre-diabetics.
- ZnT8 immunotherapy holds promise for improving beta cell function and treating T1DM.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.1K
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
01:26Antigens Involved in Adaptive Immunity
648
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
648
01:16Insulin: Dosing Regimen and Adverse Effects
240
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
240
01:40Cell-mediated Immune Responses
71.0K
Overview
71.0K
01:24Glucagon-like Receptor Agonists
402
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
402